Sage Therapeutics Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
46.66 M |
Public Float |
32.67 M |
Sage Therapeutics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$9.74 |
Market Cap |
$9.06 B |
Shares Outstanding |
51.15 M |
Public Float |
49.41 M |
Address |
215 First Street Cambridge Massachusetts 02142 United States |
Employees | - |
Website | http://www.sagerx.com |
Updated | 07/08/2019 |
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA. |